Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ARTEMISMED

ARTEMISMED

HealthcareHealthcare Services₹5435 cr market cap
₹340.00 ▼ -0.99% today As of 19 Nov 2026
52-week low ₹205.5152-week high ₹366.60

-6.3% from the 52-week high · +67.1% above the low

Artemis Medicare Services Ltd. provides health care services. The company employs 1,789 full-time employees The company went IPO on 2020-01-23. The firm is expertized in the spectrum of advanced medical and surgical interventions, a mix of inpatient and outpatient services. The firm offers treatment facilities for various medical conditions under various specialties, which include allergy and immunology, blood (haematology), bones, muscles and joints (orthopaedics), brain, spine and nervous system, cancer (oncology), circulatory (vascular), dermatology, digestive (gastroenterology), endocrine, diabetes and metabolismheart (cardiology), infectious diseases, kidneys (renal), lung (pulmonary), mouth, teeth and face (oral and maxillofacial), obstetrics and gynaecology, psychiatry, rheumatology (arthritis and joint disease), surgery and urology. The firm's subsidiary includes Artemis Cardiac Care Private Limited.

The short version. ARTEMISMED reported revenue of ₹311 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹31 crore (up 3.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 58.39% in Sep 2026, down 8.78 points over 8 quarters.

1 · The price

How has the stock traded?

ARTEMISMED trades 6.3% below its 52-week high and 67.1% above its 52-week low.

Change over period: —

1M+14.0%
3M+9.4%
6M+22.8%
1Y+21.6%

2 · The business

Is it growing?

Sales, year on year+13.1%

Sep 2026 revenue of ₹311 cr.

Profit, year on year+3.3%

Sep 2026 net profit of ₹31 cr.

Net margin10.0%

0.9 pts lower than a year earlier.

3-year growth39.0% profit

Revenue compounded at 14.3% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue311287279272275255240232
Net profit3131302230212321
Net margin %10.010.910.88.210.98.39.68.9
EPS (₹)1.961.981.91.412.161.531.671.5

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue1081937879737555408565
Net profit10483493932620
Net margin %9.68.85.65.25.71.53.5
EPS (₹)6.556.03.622.882.40.471.5

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.1% in Mar 2026; debt to equity is 0.24.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.19.911.09.6
Return on capital %13.712.212.710.1
EBITDA margin %19.319.115.813.6
Net margin %9.38.55.55.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR14.3%21.9%
Profit CAGR39.0%75.9%
Debt to equity0.24
Interest cover6.0x
Current ratio1.74
P/E ratio47.6

4 · The owners

Who holds it, and are they adding?

Promoter holding58.39%

Down 8.78 pts over 8 quarters.

Foreign institutions12.46%

Up 11.82 pts over 8 quarters.

Domestic institutions1.91%

Down 2.59 pts over 8 quarters.

Mutual fund schemes9

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter67.1767.1766.5366.5358.3958.3958.3958.39-8.78
FII0.640.310.240.3712.4712.1912.2912.46+11.82
DII4.55.044.764.272.912.892.41.91-2.59
Public20.620.3921.4621.8120.0820.3720.7621.08+0.48

Mutual fund holdings · Oct 2026

9 schemes hold this stock

7 the month before.

  • HSBC Focused Fund2.17% of NAV
  • JM ELSS - Tax Saver Fund1.47% of NAV
  • Groww BSE Hospitals ETF0.66% of NAV
  • Motilal Oswal BSE Healthcare ETF0.09% of NAV
  • Bandhan BSE Healthcare Index Fund0.09% of NAV
  • Motilal Oswal BSE 1000 Index Fund0.01% of NAV
  • ADITYA BIRLA SUN LIFE BSE TOTAL MARKET ETF0.01% of NAV
  • ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ARTEMISMED are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ARTEMISMED

What is the ARTEMISMED share price?

ARTEMISMED (ARTEMISMED) last closed at ₹340.00, down 0.99% on the day. Its 52-week range is ₹205.51 to ₹366.60.

What is the market cap of ARTEMISMED?

ARTEMISMED has a market capitalisation of about ₹5,435 crore. Its price-to-earnings ratio is 47.6.

How are ARTEMISMED's latest results?

ARTEMISMED reported revenue of ₹311 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹31 crore (up 3.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 58.39% in Sep 2026, down 8.78 points over 8 quarters.

Who owns ARTEMISMED?

As of Sep 2026, shareholding was: Promoter 58.39%, FII 12.46%, DII 1.91%, Public 21.08%.

How many mutual funds hold ARTEMISMED?

9 mutual fund schemes held ARTEMISMED in October 2026. That compares with 7 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 10 Jul 2026 · Final Dividend - Rs. 0.45
  • 11 Jul 2025 · Final Dividend - Rs. 0.45
  • 05 Jul 2024 · Final Dividend - Rs. 0.45
  • 14 Jul 2023 · Dividend - Rs. 0.45
  • 23 Sep 2021 · Stock Split From Rs.10/- to Rs.1/-

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.